Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial

S Hiltbrunner; C Britschgi; P Schuberth; L Bankel; T D L Nguyen-Kim; P Gulati; W Weder; I Opitz; O Lauk; C Caviezel; H Bachmann; A Tabor; P Schröder; A Knuth; C Münz; R Stahel; O Boyman; C Renner; U Petrausch; A Curioni-Fontecedro

doi:10.1016/j.annonc.2020.10.474

Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial

Ann Oncol. 2021 Jan;32(1):120-121. doi: 10.1016/j.annonc.2020.10.474. Epub 2020 Oct 21.

Authors

S Hiltbrunner¹, C Britschgi¹, P Schuberth¹, L Bankel¹, T D L Nguyen-Kim², P Gulati³, W Weder⁴, I Opitz⁴, O Lauk⁵, C Caviezel⁵, H Bachmann¹, A Tabor⁶, P Schröder⁶, A Knuth¹, C Münz³, R Stahel⁷, O Boyman⁸, C Renner⁹, U Petrausch¹⁰, A Curioni-Fontecedro¹¹

Affiliations

¹ Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland.
² Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
³ Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
⁴ Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
⁵ Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
⁶ Biontech Innovative Manufacturing Services, Idar-Oberstein, Germany.
⁷ Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
⁸ Department of Immunology, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
⁹ Faculty of Medicine, University of Basel, Basel, Switzerland; Onkozentrum Zürich, Swiss Tumor Immunology Institute, Zurich, Switzerland.
¹⁰ Faculty of Medicine, University of Zurich, Zurich, Switzerland; Onkozentrum Zürich, Swiss Tumor Immunology Institute, Zurich, Switzerland.
¹¹ Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland. Electronic address: alessandra.curioni@usz.ch.

PMID: 33098996
DOI: 10.1016/j.annonc.2020.10.474

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Fibroblasts
Humans
Lung Neoplasms* / drug therapy
Mesothelioma* / drug therapy
Mesothelioma, Malignant*
Pleural Neoplasms* / drug therapy
T-Lymphocytes